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Diabetes mellitus (DM) is a recognized cognitive impairment risk factor. Even with 
hyperglycemia being a modifiable risk factor in dementia, primary care is without an 
evidence-based screening tool to screen patients with diabetes for cognitive abilities. 
Current literature supports developing an evidence-based standardized guideline for early 
screening for cognitive impairment in elderly patients with DM. The purpose of this 
doctor of nursing practice (DNP) clinical practice guideline (CPG) project was to develop 
an evidence-based CPG for early screening of dementia in patients with DM, providing a 
means for early recognition of cognitive decline in these patients, making early 
intervention more likely to occur. The model informing this DNP CPG project was the 
Leavell and Clark levels of prevention; the AGREE II tool was used to develop and 
evaluate the CPG. Five content experts were asked to evaluate the newly developed CPG. 
The newly developed CPG satisfied all 23 items of the AGREE II tool with the expert 
panel concluding that the guidelines would enhance patient outcomes. The CPG is an 
innovative approach that combines recommendations and emerging guidelines to provide 
early dementia screening in DM. This guideline can improve practice and create a culture 
that embraces improvement in quality care. This newly developed CPG contributes to 
social change by addressing a severe problem in a vulnerable population, improving 
patient outcomes and quality of life. The CPG is appropriate for use in similar settings 
caring for patients with DM as hyperglycemia is common in this population and a risk 
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Section 1: Nature of the Project 
Introduction 
Diabetes mellitus (DM) is a chronic illness affecting approximately 26 million 
people in the United States (Gatlin, 2014). Adults with DM are at an increased risk for 
brain atrophy and cerebrovascular disease, leading to cognitive deficits, cognitive 
impairment, and dementia (Espeland et al., 2016). Diabetes is a recognized cognitive 
impairment risk factor, with evidence showing that it affects performance in many 
cognitive domains and puts people at increased risk of dementia (Rawlings et al., 2017). 
With no guideline in place at the primary care site where this Doctor of Nursing 
Practice (DNP) project was carried out , patients with DM were not being screened for 
cognitive impairment, creating a gap in nursing practice that was the focus of this project. 
In carrying out this clinical practice guideline (CPG) DNP project, I developed evidence-
based interventions to provide healthcare consumers and the profession with 
interventions to minimize memory loss and to optimize self-care management in adult 
patients with DM. The current primary care practice focus is on hyperglycemia and the 
immediate patient problems such as symptomatic fever and hypertension. Nursing staff 
does not routinely ask patients questions to identify potential cognitive decline, only 
asking questions if the patient shows a significant mental status decline. This lack of 





The problem of cognitive decline in DM is a difficult one to address. Patients and 
families may not even be aware that cognitive decline is a consequence of 
hyperglycemia. Salinas et al. (2016) found that study subjects with DM had almost 
double the risk of developing cognitive decline as patients without DM. The authors’ 
findings highlight the importance of the cognition evaluation and improved control in 
subjects with diabetes to avoid cognition impairment in these patients. Mild cognitive 
impairment may be preceded by 5 years of the clinical onset of dementia; however, a 
large proportion of dementia cases will never be diagnosed or will be diagnosed in a late 
stage because the diagnosis in primary health care is based on clinical suspicion.  
The prevalence of dementia is often underestimated, believed to range from 1.3% 
at ages 60-64 to over 35% in people older than 85 years of age (Katsaouni et al., 2017). 
The general practitioner must promptly identify the symptoms of dementia, that can be 
challenging to recognize. It is estimated that the earliest recognition of dementia is 
between 1 to 5 years from onset. The primary care clinic where this DNP CPG project 
was carried out has seen over 2,000 patients, and of these, over 50% are older than 65 
years and have DM with dementia. For a dementia diagnosis to happen, a person or 
someone close to them, must first identify a problem, associate that problem with 
dementia, and decide to seek medical help.  
Although a general public population study indicated that people would seek 
advice if they noticed memory problems in themselves or someone else, other studies 
based on reality instead of hypothetical situations have suggested a markedly different 
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picture (Perry-Young et al., 2018). For example, studies of actual dementia trajectories 
reported averages of between 8 and 52 months from first signs of dementia to first 
medical consultation. Several possible explanations have been offered for the delay in 
seeking treatment to include stigma and embarrassment, the most common reasons for 
the delay in help-seeking (Perry-Young et al., 2018).  
At the local level, a CPG would provide a readily available tool for routine 
screening for dementia in patients with DM. This screening tool could assist nurse 
practitioners in providing early intervention services to these patients to proactively 
address anticipated cognitive impairment to increase self-care management 
empowerment. At the organizational level, nursing leaders could share the newly 
developed CPG for inclusion in educational training programs nationally and globally for 
higher quality of care and better outcomes measures. Practice guidelines inside a 
community healthcare organization offer a framework for turning evidence into practice 
and improving outcomes (White et al, 2016).The intended improved standard of care 
could lead to actions that promote the worth and dignity of individuals with DM, 
resulting in an improved quality of life. 
Purpose Statement 
The purpose of this DNP project was to develop an evidence-based CPG for early 
screening of dementia in patients with DM that would provide a means for early 
recognition of cognitive decline in these patients, making early intervention more likely 
to occur. At the DNP project site, a large private primary care practice, the care of the 
patient with DM is guided by past practice, habit, and the presenting of chief complaints 
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by the patient. Patients with DM were not screened routinely or adequately for cognitive 
abilities nor are screenings conducted at properly spaced intervals with a recognized, 
validated tool. Rather, a cognitive evaluation may take place if the patient is overtly 
displaying evidence of cognitive decline, not as a routine practice.  
Because cognitive impairment often remains unrecognized, routine screening for 
cognitive impairment in elderly patients with DM is increasingly advocated. Janssen et al. 
(2019) provided the argument that routine screening may help clinicians in identifying 
patients with cognitive impairment who might then benefit from a personalized 
intervention (Janssen et al., 2019). A CPG could be a method to enhance early 
recognition making it less difficult to decrease or prevent cognitive decline in patients 
with DM and address the gap in practice at the DNP project setting. Thus, I answered the 
following practice-focused questions in this DNP project: Does the literature support the 
development of a CPG for early recognition of cognitive impairment in patients with 
DM? and Can an evidence-based CPG be developed and validated regarding early 
recognition and prevention of dementia in DM? 
Nature of the Doctoral Project 
I used the following databases to conduct a comprehensive literature search of 
peer-reviewed journals: Medline, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), Cochrane Library, Joanna Briggs Institute, Health Source, 
PubMed, Google Scholar, and National Guidelines Clearinghouse. The literature search 
criteria included peer-reviewed articles, in English, and written between 2014 and 
present. Diabetes AND dementia AND prevention were the primary search terms used for 
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the search. Websites of professional nursing associations, such as the American Nurses 
Association and the American Diabetes Association, were searched for available 
resources on DM and early dementia screening.  
Using Walden University’s Manual for Clinical Practice Guideline Development, 
I developed evidence-based criteria for the extensive literature search. The criteria for 
including sources were that they must be peer-reviewed, in English, and written between 
2014. My search for literature continued until references were redundantly identified, 
leading to 606 articles that I reviewed for topical relevance, leaving 150. These were 
further reduced to only one with significance to the CPG development based on usability 
at the project site that I reviewed for inclusion in the CPG. Using the step-by-step 
appraisal tool of Fineout-Overholt et al. (2010), I critically appraised the literature and 
organized the relevant articles into a literature matrix (see Appendix A). After approval 
from Walden University Institutional Review Board and the facility, I developed the CPG 
from the evidence-based literature and obtained feedback on the newly developed CPG 
from five content experts, using the Appraisal of Guidelines, Research, and Evaluation 
(AGREE II) instrument’s guidelines. No revisions were recommended based on feedback 
from the expert panel. The gap in practice was successfully addressed by developing a 
CPG for early screening of dementia in patients with diabetes.  
Significance 
Health-related quality of life measures the effect of a disease or treatment on one's 
physical, psychosocial, and social functioning (Abualula et al., 2016). According to 
Abualula et al. (2016), diabetes has been shown to reduce a person’s quality of life. 
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Patients and their families will be positively impacted by the implementation of early 
screening for dementia as it will improve the patients’ health outcomes and quality of 
lives and delay the development of dementia (Salinas et al., 2016). Evidence-based 
interventions could provide healthcare consumers and the profession with options to 
minimize memory loss and optimize self-care management in adult patients with DM, 
thus improving the quality of care.  
Identified stakeholders for the CPG included the organization, patients, and staff. 
It is anticipated that the CPG implementation will provide ways to postpone or even 
avoid dementia in patients with DM and help improve the quality of life for these patients 
(Salinas et al., 2016). At the local level, such knowledge could assist nurse practitioners 
who provide early intervention services to patients diagnosed with DM to proactively 
address anticipated cognitive impairment that will provide self-care management 
empowerment to patients. The organization and the patient will benefit from 
implementing the CPG because unrecognized cognitive impairment can impact 
adherence to treatment and diabetes self-management, resulting in poor glycemic control, 
an increased frequency of severe hypoglycemic episodes, and hospital admissions. The 
early diagnosis of cognitive impairment is not only recommended for all these reasons 
but may also permit us to offer more personalized treatment for DM patients (Simo et al., 
2017).  
Beyond the local level, the newly developed CPG could be shared with regional 
and national providers and included in professional training programs, thus providing the 
resources needed for interventions and treatment for improved outcomes. With this 
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change of practice, screening and evaluation should improve the quality of treatment and 
patient outcomes for patients with DM with potential cognitive decline.  
Implementation of the CPG may also improve the quality of care and quality of 
life of individuals by raising the awareness of Americans with a family history of 
diabetes and dementia of the positive changes and preventive health behaviors they can 
undertake to postpone the development of dementia. Health care providers and key 
stakeholders could devise a framework for policymakers on diabetes and dementia 
prevention using the information provided from the analysis. A desirable social change 
will be prevention of dementia, considering the resulting impairment, morbidity, 
mortality, and financial cost of this disease to members of society. Through this project, I 
provided an action plan to promote the worth and dignity of individuals with DM that is 
anticipated to improve health outcomes and quality of life. The newly developed CPG 
can be transferred to any clinical setting caring for patients with DM as the pathology and 
progression for dementia are the same. The CPG will help establish a proper treatment 
plan for any provider by providing protocols for dementia prevention/treatment 
intervention in patients with DM. 
There are an estimated 35.6 million people with dementia worldwide; by 2050, 
the number will increase to more than 115 million (Bunn et al., 2016). Dementia and DM 
are common long-term disorders that can coexist for many older people. In the absence of 
a cure, people with dementia require prompt diagnosis and evidence-based treatment to 
delay disease progression and enhance health-related quality of life (Michalowsky et al., 
2019). Globally, a remarkable increase in life expectancy and population aging continues 
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that could lead to an increase in DM and dementia; according to the Centers for Disease 
Control and Prevention (2011), a 4.5-fold increase is expected in the incidence of 
diabetes in the elderly population over 65 years of age, compared with a 3-fold rise in the 
overall population, between 2005 and 2050 (Kim et al., 2019). DM is one of the world's 
leading chronic illnesses that cause impairment and mortality and is a major contributing 
factor to dementia.  
Summary 
Cognitive impairment caused by dementia is a deleterious effect of hyperglycemia 
that affects the individual’s ability to plan a diet, monitor and treat blood glucose levels, 
and regulate physical activity (Gatlin, 2014). Diabetes is a recognized risk factor for 
cognitive impairment, with evidence showing that it affects performance in numerous 
cognitive domains and puts persons at increased risk of dementia (Rawlings et al., 2017). 
Because cognitive impairment often remains unrecognized, routine screening for 
cognitive impairment in elderly patients with DM is increasingly advocated (Janseen et 
al., 2019). The practice-focused questions that guided the DNP project were: Does the 
literature support the development of a CPG for early recognition of cognitive 
impairment in patients with DM? and Can an evidence-based CPG be developed and 
validated regarding early recognition and prevention of dementia in DM? The overall 
goal was to close the gap in practice that is the lack of screening to address the potential 
cognitive decline in DM patients. A CPG is a way to decrease or prevent dementia in DM 
(Espeland et al., 2016). In Section 2, I discuss the model, relevance to nursing practice, 
local background and context, and the role of the DNP student.   
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Section 2: Background and Context 
Introduction 
Screening patients diagnosed with DM for early signs of cognitive impairment 
during routine office visits may enable practitioners to develop plans of care to decrease 
or retard the progression of cognitive decline. Nurses in this private internal medicine 
practice did not screen patients for early signs of dementia. Personal communication with 
the physicians and nurses at this facility revealed that they were not knowledgeable about 
the most current evidence-based practice related to early screening for signs of dementia. 
The purpose of the DNP project was to develop an evidence-based CPG for early 
screening of dementia in patients with DM. The practice-focused questions that guided 
the DNP project were: Does the literature support the development of a CPG for early 
recognition of cognitive impairment in patients with DM? and Can an evidence-based 
CPG be developed and validated regarding early recognition and prevention of dementia 
in DM? A practice CPG is the most appropriate way to decrease or prevent dementia in 
DM (Espeland et al., 2016). In Section 2, I describe the model, relevance to nursing 
practice, local background and context, and the role of the DNP student.  
Concepts, Models, and Theories 
Leavell and Clark Levels of Prevention Model 
The model informing this DNP CPG project was the Leavell and Clark (1958) 
levels of prevention. Leavell and Clark first documented prevention in 1953, outlining 
three levels of prevention—primary, secondary, and tertiary—in their classic model that 
correlate with the disease's progression. Each of the three stages of prevention is 
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implemented at the appropriate phase of pathogenesis to delay development (Leavell & 
Clark, 1958). Thus, initiatives at the primary prevention level focus on general health 
promotion and specific protection, such as promoting a healthy diet and encouraging 
regular exercise. Secondary prevention is concerned with early detection by screening 
examinations and prompt treatment, including any screening measures and subsequent 
efforts to limit dementia and diabetes progression. Next, tertiary prevention covers 
disability limitation and rehabilitation (Leavell & Clark, 1958).  
There are many examples of applying primary prevention strategies in nursing 
practice, including efforts to prevent poly-pharmacy among community-dwelling older 
adults (Harvath et al., 2016); maternal morbidity and mortality (Logsdon, 2016); 
multidrug-resistant, gram-negative infection in surgical patients (Murphy, 2012); falls 
among older adults (Morgan et al., 2017); and cardiovascular disease through the use of 
statins (Sherrod et al., 2015). Some excellent examples targeted at secondary-prevention 
nursing strategies include a program guideline for screening depression in adolescents 
with diabetes (Denver, 2016); a campaign to encourage perinatal depression screening 
among beneficiaries of the Special Supplementary Nutrition Plan for Mothers, Infants, 
and Children (Fritz, 2015); discussion of the value of screening for oral cancer linked to 
human papillomavirus (Katz, 2017); screening for elder abuse (Stark, 2012); and 
community-based screening for colorectal cancer (Weyl et al., 2015). Tertiary prevention 
initiatives provide information to help nurses work to allow colorectal cancer survivors to 
follow up on colorectal guideline recommendations (Hawkins et al., 2015), prevent 
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hemodialysis complications by encouraging exercise (Hannan, 2016), and avoid tumor 
lysis syndrome among cancer patients (Kaplow & Iyere, 2016).  
Leavell and Clark's prevention levels is an ideal structure within which to develop 
a treatment plan; nursing interventions at each level of prevention may be proposed using 
this classic framework (Bissett, 1986). The prevention model was essential to this project 
because an evidence-based CPG for early dementia screening in patients with DM will 
provide information that clinicians can use to develop individualized plans of care that 
incorporate all prevention levels for patients with DM.  
AGREE II 
I used the AGREE II instrument (AGREE Next Steps Consortium, 2017) as a 
guideline to develop the CPG, and the expert panel used this same instrument to evaluate 
the newly developed CPG. The AGREE II tool was developed to address the 
inconsistency in guideline quality with the purpose of the AGREE II tool being to guide 
the development and evaluation of the quality of practical guidelines that are candidates 
for use in clinical practice across the health continuum, to formulate policy-related 
decisions, or to adapt recommendations from one context to another (Brouwers et al. 
2010). As further defined, quality means addressing possible biases and that the 
recommendations are valid and feasible for practice. As described in AGREE II, this 
process also includes considering the benefits, harms, and costs of the proposals, and the 
practical issues attached to them (AGREE Next Steps Consortium, 2017).  
The AGREE II instrument has 23 items grouped into six domains: (a) scope and 
purpose, (b) the participation of key stakeholders, (c) implementation rigor, (d) clarity of 
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presentation, (e) applicability, and (f) editorial independence. The evaluators use a 7-
point response scale with a score of 1 to indicate that there is no information or that the 
concept is very poorly informed and a score of 7 to indicate that the quality of the 
reporting is exceptional and that all the criteria and considerations set out in the user 
manual have been met. Scores between 2 and 6 indicate that the reporting of AGREE II 
does not fully meet the criteria or considerations (Brouwers et al., 2010). The AGREE II 
tool was appropriate for the DNP project as it addressed the quality variability of the 
newly developed guideline. It was also used to assess the methodological rigor and clarity 
with which the guideline was developed.  
The AGREE II instrument is well recognized as an appropriate tool for evaluating 
CPGs. The nursing faculty at the Lienhard School of Nursing at Pace University, a family 
nurse practitioner program, used the AGREE instrument to critically teach family nurse 
practitioner students how to appraise CPGs. In this program, students practiced critiquing 
single studies, systematic reviews, and CPGs (Singleton & Levin, 2008). In another 
application of the AGREE instrument, a group of nurses used it to appraise the National 
Kidney Foundation Kidney Disease Outcomes Quality Initiative CPG for chronic kidney 
disease to establish best practice for renal function screening before cardiac angiography 
to prevent contrast-induced nephropathy. Based on their assessment, the expert panel 
decided that a practice change was needed to include their previous order set to reflect a 
shift in care (White et al., 2016). According to White et al. (2016), the AGREE II 
instrument uses theoretically derived criteria to evaluate CPG consistency and usefulness. 
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The AGREE instrument is designed for CPG developers to consider and recommend 
implementing a CPG, making it appropriate for this DNP CPG project.  
Definition of Terms 
Clinical practice guidelines: Guidelines for clinical practice are official 
recommendations that can include screening, diagnosis, treatment, and management of 
conditions (Singleton & Levin, 2008). 
Relevance to Nursing Practice 
There is evidence that DM is associated with cognitive decline and dementia 
(Simo et al., 2017). Due to the diabetes pandemic and the concomitant increase in aging 
populations worldwide, the number of patients with cognitive impairment or dementia is 
expected to grow. In this context, extreme cognitive impairment can be a potential long-
term complication of diabetes with dramatic consequences for affected subjects and their 
families and a significant impact on healthcare systems. There is, therefore, an urgent 
need for strategies to identify patients at risk for DM dementia (Simo et al., 2017). 
According to Biessels and Whitmer (2019), although both individuals with DM and their 
physicians are increasingly aware of cognitive impairment related to diabetes, this 
awareness still lags behind that of other complications of diabetes.  
Current State of Nursing Practice 
Over the last decade, there has been active discussion among scholars about 
cognitive impairment being an emerging DM complication often undiagnosed. Simo et 
al. (2017) argued that the diagnosis is critical because patients with DM and cognitive 
impairment are more likely to show impaired diabetes self-management, poor glycemic 
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control, and increased diabetes complications. Expanding on this idea, Larner (2018) 
contended that recent studies of new therapeutic interventions for dementia have been 
universally negative, prompting the view that prevention will be a more effective 
approach to lowering the projected increase in the number of dementia patients in the 
future and that it is not known whether patients with subjective memory complaints are at 
increased risk of subsequent cognitive impairment development and may, therefore, also 
be a suitably selected population for screening purposes. Likewise, Biessels and Whitmer 
(2019) found that patients reported that their healthcare providers often have difficulty 
communicating with diabetes-related cognitive dysfunctions. There are currently no 
phenotypic markers or unique tests recorded in clinical practice to identify patients with 
DM at risk of developing dementia. Given the rise in the global prevalence of DM with 
cognitive impairment and anticipation of improved early-stage dementia treatments, this 
gap should be closed (Simo et al., 2017).  
Previously Used Standard Practices and Strategies 
In January 2017, a new Medicare Cognitive Assessment and Care Planning billing 
code came into effect (Molony et al., 2018). It provides practitioners with reimbursement 
for a clinical visit resulting in a comprehensive care plan for persons with a documented 
cognitive impairment. The rules within the code include a multidimensional evaluation 
including comprehension, function, health, neuropsychiatric and behavioral symptoms, 
drug reconciliation, and caregiver needs assessment. Person-centered assessment and care 
planning, according to Molony et al. (2018), focuses on the unique needs and 
characteristics of the individual. Currently, many people living with dementia do not 
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receive person-centered assessment and care planning due to programmatic, 
organizational, and regulatory requirements and professional and provider practices that 
reflect the needs of staff and settings more than the needs of the patient with dementia. 
Screening for cognitive impairment is generally not recommended in the general 
population based on the argument that there is currently no disease-modifying therapy 
available to stop or slow down the processes leading to dementia; therefore, early 
identification in people without evident complaints has been suggested to be unethical, as 
early diagnosis could be stressful while there is little to be offered to those who screen 
positive (Biessels & Whitmer, 2019). According to Biessels and Whitmer (2019), the 
recommendations for diabetes management are taking a different stance, suggesting that 
early diagnosis will help avoid the risks associated with diabetes treatment and improve 
diabetes management. 
Local Background and Context 
The intended setting for this project is an independent internal medicine, primary 
care clinic in a metropolitan area of a southern state, with a mixture of racial, ethnic, 
socioeconomic, and cultural backgrounds served by two providers. In this primary care 
outpatient setting, approximately 2,000 patients have been seen. Of these, over 50% are 
older than 65 years and have DM with dementia. The care of these patients with DM is 
guided by past practice, habit, and the presenting chief complaint. Patients were not 




Without the development of a disease-modifying biomedical therapy, the number 
of people aged 65 and older with dementia may triple from 5.5 million to a projected 13.8 
million by 2050 (Thornhill & Conant, 2018). In December 2010, Congress unanimously 
passed the National Dementia Project Act that raised dementia awareness to a national 
political priority. This law led to the creation of a strategic plan, the National Dementia 
Plan, to improve care, support, and treatment (Thornhill & Conant, 2018). The annual 
wellness visit is a new benefit to Medicare under the Patient Protection and Affordable 
Care Act, creating an incentive for physicians to require an examination to diagnose 
cognitive impairment. The provision came into force in January 2011, and the 
Association produced guidelines on how to perform cognitive tests to promote the use of 
benefits by primary care providers.  
To provide cognitive evaluation guidance to primary care providers at the annual 
wellness visit, and where referral or additional examination is needed, the Alzheimer's 
Association assembled a panel of experts to develop recommendations (Cordell et al., 
2013). According to Cordell et al. (2013), the resulting Alzheimer's Association Medicare 
Annual Wellness Visit Algorithm for Assessment of Cognition includes a review of 
patient Health Risk Assessment information, patient observation, unstructured questions 
during the annual wellness visit, and the use of standardized cognitive assessment tools 
for patients and informants alike. Widespread use of this model may be the first step 
towards decreasing the incidence of missing or postponed dementia diagnosis, thereby 
allowing improved clinical management and more favorable outcomes for affected 
patients and their families and caregivers (Cordell et al., 2013). 
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The Alzheimer's Association has long advocated legislation to improve the 
detection, diagnosis, and awareness of Alzheimer’s disease and, in collaboration with the 
Centers for Disease Control and Prevention, is introducing a new federal-state awareness-
raising approach to dementia brain health, Healthy Brain Initiative: The Public Health 
Road Map for State and National Partnerships (Thornhill & Conant, 2018).The Road 
Map identifies strategies to encourage healthy cognitive functioning for state and local 
public health departments and their stakeholders, to address cognitive impairment, and to 
meet care partners' needs. The Road Map contains guidance on developing effective 
policies at the state and local level. Implementing the Public Health Road Map is a policy 
priority for the state chapters of the Alzheimer’s Associations (Thornhill & Conant, 
2018). In 2014, the Georgia Division of Aging Services, the Rosalynn Carter Institute for 
Caregiving, the Alzheimer's Association, and Georgia Public Broadcasting created and 
aired "Alzheimer's Hope for Tomorrow, Help for Today," that provided information to 
people with dementia and caregivers (Thornhill & Conant, 2018). In 2018, the 
Alzheimer's Act infrastructure (S. 2076) was signed into law. The Public Law 115-406 
was signed into law in December 2019. The bipartisan support and leadership resulted in 
an increase of $350 million for research into Alzheimer's and dementia. Additionally, the 
$10 million inclusion was provided to implement the Building Our Largest Dementia 
(BOLD) infrastructure. 
Role of the DNP Student 
My present job is in a primary care setting as a family nurse practitioner (FNP). 
One motivation for this doctoral project is a diagnosis of DM and early signs and 
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symptoms of dementia in many relatives. My observation of the clinical practice gap was 
another motivation for this DNP CPG project. The clinic has no plan in place to assist 
with an early dementia screening of the DM population. I had the primary role of a DNP 
student in developing the CPG. The absence of a clinic strategy was not due to the lack of 
desire to help patients but was due to the lack of a CPG. 
It is essential to ascertain the correlation between dementia and DM. The purpose 
of further exploring this issue was to develop a CPG that would help DM patients reduce 
dementia symptoms. As a DNP student, I searched for current evidence and used the 
Fineout-Overholt (2010) model to grade the evidence used in the development of the 
CPG. The CPG was based on the best evidence, using the Leavell and Clark's levels of 
prevention model, the Walden University Manual for Clinical Practice Guideline 
Development, and the second edition of the AGREE II tool (AGREE Next Steps 
Consortium, 2017). Once the CPG was in draft form, I asked a panel made up of five 
content experts including two primary care physicians (who own the practice), one staff 
Licensed Practical Nurse, one staff FNP, and one Adult-Gerontology Nurse Practitioner 
with clinical DM expertise to review the CPG using the 23 items Agree II instrument. 
Revisions were not required after the expert panel agreed to the CPG's appropriateness. 
No potential biases were identified in the DNP project. 
Summary 
Diabetes is a recognized risk factor for cognitive impairment, with evidence 
showing that it affects performance in numerous cognitive domains and puts persons at 
increased risk of dementia. Patients were not routinely screened for cognitive decline at 
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the primary care site creating a gap in nursing practice. The purpose of the DNP project 
was to develop an evidence-based CPG for early screening of dementia in patients with 
DM to close the gap in practice by developing a CPG for early screening of dementia in 
patients with diabetes. The newly developed CPG will provide a means for early 
recognition of cognitive decline in patients with DM. The model informing this DNP 
CPG project was the Leavell and Clark (1958) levels of prevention model. The levels of 
prevention model was essential to this project because the evidence-based CPG for early 
dementia screening in patients with DM will provide information that clinicians can use 
to develop individualized plans of care that incorporate all levels of prevention for 
patients with DM.  
Due to the diabetes pandemic and the concomitant increase in aging populations 
worldwide, the number of patients with cognitive impairment or dementia is expected to 
grow. In this context, extreme cognitive impairment can be a potential long-term 
complication of diabetes with dramatic consequences for affected subjects and their 
families and a significant impact on healthcare systems. As a DNP student, I had a central 
role in developing the CPG and received support from the staff during this process. My 
motivation for this DNP CPG project was based on my observation of the clinical 
practice gap. The clinic does not have a strategy in place to help the DM population with 
an early screening of dementia.  
Section 2 introduced the AGREE II model to frame the development and scoring 
of the evidence-based CPG for early dementia screening in DM patients that will provide 
health-care professionals with information on the importance of the CPG. I have also 
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examined the background of the problem and defined my role and the role of the 
participants in developing a CPG for early dementia screening in DM patients. The gap 
has been identified in practice as not having a CPG at the local practice site; in 
comparison, the literature evidence has indicated early dementia screening in DM 
patients could close this gap (Janseen et al., 2019). In Section 3, I recount the purpose of 
this DNP project. I will present the practice-focused questions, describe sources of 
evidence, analyze, synthesize the evidence, and conclude with a summary. 
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Section 3: Collection and Analysis of Evidence 
Introduction 
Diabetes is a recognized risk factor for cognitive impairment, with evidence 
showing that it affects performance in numerous cognitive domains and puts persons at 
increased risk of dementia. Through this DNP project, I developed an evidence-based 
CPG for early screening of dementia in patients with DM at an independent, internal 
medicine, primary care clinic where patient care for patients with DM has been guided by 
past practice, habit, and presentation of a substantial complaint. These patients have not 
been routinely or adequately screened for cognitive abilities, nor have screenings been 
carried out at appropriately spaced intervals with a recognized, validated tool. By 
developing a CPG for early screening of dementia in patients with diabetes, I addressed 
the gap in practice. A desirable social change is dementia prevention, considering the 
resulting impairment, morbidity, mortality, and financial cost of dementia to members of 
society; through the development of a CPG, I provided an action to decrease these 
impairments and promote the worth and dignity of individuals with DM that can improve 
their quality of life. The practice problem is discussed in the following section of the 
paper, along with the local problem, sources of evidence, and the analysis and synthesis 
methods.  
Practice-Focused Questions 
At the DNP project site, a large private primary care practice, the care of the 
patient with DM has been guided by past practice, habit, and the presenting chief 
complaint of the patient. These patients with DM were not adequately screened for 
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cognitive abilities; early detection screening for cognitive impairment is not performed 
consistently nor with a recognized and validated tool at regularly spaced intervals, rather 
a cognitive test may take place only if the patient demonstrates signs of cognitive 
impairment. A CPG is anticipated to enhance early recognition in cognitive decline in 
patients with DM and address the gap in practice at the DNP project setting, the argument 
being that routine screening may identify patients with cognitive impairment who might 
then benefit from a personalized intervention (Janssen et al., 2019). Thus, the practice-
focused questions that guided the DNP project were: Does the literature support the 
development of a CPG for early recognition of cognitive impairment in patients with 
DM? and Can an evidence-based CPG be developed and validated regarding early 
recognition and prevention of dementia in DM?  
Sources of Evidence 
CPGs direct practitioners to deliver quality treatment and provide clinicians with 
a standard of care aimed at positive patient outcomes and may include screening, 
diagnosis, treatment, and management of specific conditions. CPGs provide the 
foundation for clinical protocols that practitioners use (Singleton & Levin, 2008). 
Sources of evidence for this CPG project were gathered from an in-depth literature search 
of peer-review journals. From the 66 research studies and articles that were found 
pertinent, these were further reduced to only one with significance to the CPG 
development because it met usability criteria at the project site. Collecting data and 
evidence from the Alzheimer's Association recommendations for operationalizing the 
detection of cognitive impairment during the Medicare Annual Wellness Visit in a 
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primary care setting added to the information considered in the development of the CPG 
to fit the needs of the target facility. The AGREE II results from the expert panel 
evaluations were a second source of evidence.  
Participants  
The practice guideline was presented to the expert panel consisting of five key 
stakeholders: two physician co-owners of the practice, one staff LPN, one staff FNP, and 
one offsite AGNP with clinical DM expertise. These members were in positions of 
authority at the practice site and are decision-makers in adopting new policies. They were 
also the end users of this project.  
Procedures 
After an exhaustive review of the literature and development of the literature 
matrix (see Appendix A), following the AGREE II instrument guidelines, I developed an 
evidence-based CPG for early recognition of cognitive impairment in patients with DM. 
After I developed the CPG, I distributed copies to the expert panel, who then evaluated 
the CPG using the AGREE II tool. The validity and reliability of the AGREE II are well-
known to be reproducible in DNP projects (Brouwers et al., 2010). After reviewing the 
AGREE II scores, no revisions were required because the expert panel reached a 
consensus that the CPG was appropriate. The CPG will be submitted to administration by 
the practice owners. 
Protections 
This CPG DNP project was aligned with the Walden University Manual for 
Clinical Practice Guideline Development and approval was obtained from Walden 
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University’s Institutional Review Board (Approval no. 09-08-20-0501311) and the 
facility signed the CPG doctoral project approval form. Each expert panelist received the 
preapproved Disclosure to Expert Panelist form (see Appendix B). The reviewers 
remained anonymous with all paperwork identified with numbers rather than names. The 
facility was only referred to in general terms to prevent recognition. 
Analysis and Synthesis 
The literature review matrix was used to summarize the available evidence-based 
literature that I used to develop the CPG. I used the AGREE II scores and a summative 
and formative evaluation to collect data that were analyzed and synthesized for the DNP 
project. The AGREE II is a tool developed to address the variability in guideline quality 
and assess the methodological rigor and transparency with which guidelines are 
developed, including what information will be presented in guidelines and how (AGREE 
Next Steps Consortium, 2017). The AGREE II instrument comprises 23 items and six 
quality domains: (a) scope and purpose, (b) stakeholder involvement, (c) rigor of 
development, (d) clarity of presentation, (e) applicability, and (f) and editorial 
independence. The AGREE II scores were averaged manually assuring integrity and 
accuracy. 
Summary 
At the internal medicine practicum site, the patients with DM were not routinely 
or adequately screened for cognitive abilities, nor were screenings carried out at 
appropriately spaced intervals with a recognized, validated tool. The purpose of this DNP 
project was to develop an evidence-based CPG for early screening of dementia in patients 
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with DM. The gap in practice was addressed by my developing a CPG for early screening 
of dementia in patients with diabetes. The adoption of the proposed practice guideline 
with accompanying support materials will potentially change how providers treat patients 
with an anticipated decrease in dementia in the patient with DM  
Section 3 of this DNP project outlined the approach used to develop the CPG for 
early screening of dementia in DM patients. Articles supporting this topic were organized 
into a literature matrix. An expert panel evaluated the CPG using the AGREE II tool. I 
used the AGREE II scores and a summative and formative evaluation to analyze and 
synthesize the DNP project data. In Section 4, I discuss the DNP project results and 




Section 4: Findings and Recommendations 
Introduction 
DM places patients at an increased risk of brain atrophy and cerebrovascular 
disease, leading to cognitive deficits, cognitive impairment, and dementia (Espeland et 
al., 2016). DM is a chronic disease affecting approximately 26 million people in the 
United States (Gatlin, 2014). With no guidelines in place at the DNP project's primary 
care site, patients with DM were not being screened for cognitive impairment. This lack 
of regular screening for cognitive impairment created a nursing practice gap. The 
practice-focused questions this DNP CPG project addressed were: Does the literature 
support the development of a CPG for early recognition of cognitive impairment in 
patients with DM? and Can an evidence-based CPG be developed and validated 
regarding early recognition and prevention of dementia in DM? The purpose of the DNP 
project was to develop an evidence-based CPG for early screening of dementia in patients 
with DM that will provide a means for early recognition of cognitive decline in these 
patients, making early intervention more likely to occur.  
After an exhaustive review of the literature, I developed the literature matrix (see 
Appendix A) to organize the evidence and rate the studies' strength for the development 
of a CPG (see Appendix C). Following the AGREE II (AGREE Next Steps Consortium, 
2017) instrument guidelines, I developed an evidence-based CPG for early screening of 
cognitive impairment in patients with DM from the selected literature. The AGREE II 
tool was used by an expert panel to evaluate the newly developed CPG, and the scores 
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were averaged by hand. In Section 4, I address, along with recommendations, the 
findings and the strengths and limitations of the project. 
Findings and Implications 
Through my literature review, I found one article (Cordell et al., 2013) that 
provided guidelines that were appropriate for the target setting. Based on this evidence-
based literature, I developed a CPG to be considered for implementation at the facility. 
The expert panel then evaluated the CPG for consistency and quality using the AGREE II 
tool (Brouwer et al., 2017). Each item of the six domains was graded using a 7-point 
scale. A score of 7 represented strongly agree, whereas a score of 1 represented strongly 
disagree. The panel was given 7 days to complete and return the AGREE II tool, and they 
all met the deadline. The 23 criteria of the AGREE II tool were grouped in six domains, 
with each domain representing a different guideline area (see Table 1).  
Table 1 
 
AGREE II Clinical Guideline Evaluation Tool Scores 



































1 19 21 55 20 28 14 7 
2 20 19 33 20 25 14 7 
3 21 19 51 19 25 12 6 
4 21 21 56 21 28 14 7 
5 21 21 56 20 28 14 7 
Percentage 97 96 90 95 96 97 97 




Domain 1 addressed the guideline's scope and overall purpose, to include the 
health issue that was scored as clearly defined. The population that the guideline was to 
refer to was listed explicitly. The total score of this domain was 97%. Evaluator 1 
suggested that dementia with diabetes should exclude the younger population with DM. 
However, there was no explanation for this suggestion.  
Domain 2 focused on the guideline development with relevant professional 
group’s inclusion, views, and preferences of the target population. The content panel 
scored Domain 2 at 96%, concurring that the guideline development group included 
individuals from all relevant professional groups, that all professional groups were 
important, and that the guideline was clearly defined and the criteria were met. An 
evaluator commented that "nurse practitioners and physician assistants can play more of a 
primary role along with the doctors." 
Domain 3 addressed the rigor of development. It focused on what methods were 
used to search for evidence, criteria for selecting evidence, strengths, limitations of the 
evidence, and procedures for updating the guideline. The expert panel scored Domain 3 
at 90%, agreeing that experts have externally reviewed the guideline before publication, a 
complete reference list was provided for primary care providers, a procedure for updating 
the guideline was provided, and a 3-year guideline review is adequate for monitoring. 
The expert panel agreed that there is an explicit link between the recommendations and 
the supporting evidence. A question posed by Evaluator 5 was, "Does cognitive 
impairment relate to noncompliance and poor diabetic control?" This question was 
answered based on my previous discussion in the literature review.  
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Domain 4 addressed the clarity and presentation, including recommendations, 
options for management of the health issue, and key recommendations. The expert panel 
scored Domain 4 at 95% offering no comments.  
Domain 5 addressed the applicability of the CPG that focused on facilitators and 
barriers to its application, tools on how the recommendations can be put into practice, 
potential resource implications, and monitoring criteria in the future. The total score for 
this domain was 96%. The expert panel commented that the guideline provides advice 
and tools on how the recommendations can be put into practice and that “the tools are 
very simple and easy to do in primary care and monitoring and auditing criteria is well 
defined." There were no other comments in Domain 5.  
Domain 6 addressed editorial independence that focused on the funding body's 
views not influencing the guideline's content and competing interests of guideline 
development. There was no funding required for this project. The domain received a 
score of 97 %. The expert panel commented that the "funding bodies should not influence 
study and guideline." 
In the Overall Guideline Assessment, the expert panel scored CPG at 100%, with 
all evaluators stating that they would recommend the CPG for use as presented. Evaluator 
2 noted that the overall quality of this guideline was "excellent quality”, and the expert 
panel stated the CPG was nicely written, well organized, and much needed inside the 
practice environment. The expert panel concluded that the guidelines would enhance 
patient outcomes and, considering the resulting impairment of dementia, morbidity, 
mortality, and financial cost to society members, dementia prevention is a desirable social 
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change. Also, the expert panel agreed that the organization and the patients would benefit 
from implementing a CPG because unrecognized cognitive impairment can impact 
adherence to treatment and diabetes self-management, resulting in poor glycemic control, 
an increased frequency of severe hypoglycemic episodes, and hospital admissions.  
There is a need to find methods that improve cognitive impairment in DM 
patients continually. This project contributed to nursing practice by adding new 
information on the development and use of an evidence-based CPG to guide nursing care. 
The project synthesized evidence-based details to develop a process for DM patients to 
postpone or avoid cognitive impairment. Through the CPG implementation, it is 
anticipated that cognitive impairment in the DM patients will decrease, quality of life for 
the patients will improve, and financial burden on society will be decreased, thus creating 
a positive social change. The project results can be used as baseline information for 
future projects and or research.  
The project may contribute to the development of additional guidelines in nursing 
practice. The worldwide prevalence of diabetes and dementia in people older than 65 is 
estimated to double over the next three decades (Biessels & Whitmer, 2019). According 
to Biessels and Whitmer (2019), data from a large veteran's registry in the US showed 
that among people with diabetes, the prevalence of dementia and cognitive impairment 
combined was 13.1% for individuals aged 65-74 years and 24.2 % for those aged 75 
years and older. The use of the developed EBP guideline can positively impact health 
outcomes and improve and standardize the nursing practice approach. The guideline has 




The gap in practice was addressed by providing a CPG for primary care providers 
to use for early screening for cognitive impairment in DM. CPGs direct practitioners to 
deliver quality treatment and provide clinicians with a standard of care aimed at positive 
patient outcomes. They provide the foundation for clinical protocols that practitioners use 
(Singleton & Levin, 2008). The expert panel recommended the CPG be implemented for 
use by adding it to the assessment packet for all patients with DM. Implementing the 
CPG in primary care is an innovative approach that will improve practice and create a 
culture that embraces improved quality care for social change. The CPG adoption could 
help nurse practitioners provide DM patients with early intervention resources to treat 
anticipated cognitive impairment to improve self-care empowerment proactively. The 
project plan is for the proposed recommendation to be introduced to the facility 
administration for potential implementation. 
Strengths and Limitations of the Project 
This CPG project's positive aspects included the chance to find an expert panel of 
qualified and devoted professionals to participate and a platform to carry out the project. 
An additional strength was the opportunity to identify appropriate, peer-reviewed 
literature to use in the process of developing a CPG that is ideal for the target population. 
Another value of the project is that, since the pathology and progression are the same, the 
study outcomes can be applied to any clinical environment that cares for patients with 
DM. By providing an assessment for early dementia screening in patients with DM, the 
CPG can provide a course of an appropriate treatment plan for any provider. The main 
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limitation I faced during the project was that there was not a CPG for early screening for 
cognitive impairment in DM, although it is supported throughout the literature. 
For future CPG projects, I would add an information technology (IT) participant 
to assist with incorporating the newly developed guidelines into the electronic health 
record. With IT’s involvement, hard stops could trigger the nurse to complete the 
assessment and the information would become a part of the permanent record. Other 
future projects to be considered include validating different current and evolving 
screening tools such as iPad applications and gait tracking, resulting in new instruments 
being recognized as more suitable and realistic for primary care evaluation of cognitive 
impairment. 
Summary 
The CPG development for early screening for dementia in DM was addressed in 
this section. The strength of the project was the ability to define relevant, peer-reviewed 
literature to be used to develop a CPG that is appropriate for the study population. The 
main limitations I faced were that, although there were recommendations and screening 
was endorsed in the literature, there was no CPG for early screening of DM for cognitive 
impairment. The expert panel's AGREE II evaluations recognized the quality of the 
newly developed CPG; the expert panel suggested introducing it to the facility 
administrators for potential implementation. I address the plan for dissemination as well 
as an analysis of myself in Section 5. 
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Section 5: Dissemination Plan 
The plan is for the newly developed CPG for early screening for dementia in DM 
be introduced to the facility administration for implementation. My plan for 
disseminating beyond the target setting is to have the CPG published in a peer-reviewed 
journal such as the Walden University Journal of Excellence in Nursing Healthcare 
Practice or the American Association of Nurse Practitioners. Also, I plan to publish 
dementia and DM articles in the Case Management Society of America’s official journal, 
Professional Case Management: The Leader in Evidence-Based Practice. These journals 
have robust platforms with a diverse population of professional nurses, some of whom 
work in primary care settings where DM and cognitive impairment is common.  
Analysis of Self 
My upbringing nurtured my core beliefs of family, community, loyalty, 
compassion, and trustworthiness. I was taught that anything worthwhile requires hard 
work. I began my nursing career as a nurse aide at the age of 16. I fell in love with 
nursing and taking care of patients. I particularly liked seeing patients get better. I 
decided at an early age to pursue a career as a nurse. This desire led to my ADN, then 
BSN, then an MSN, and now a DNP. Nursing is a passion of mine. I love this profession; 
it is an enriching career that allows me to serve my community.  
Practitioner 
As an FNP and working at the bedside, I was able to identify the practice problem 
for this project. I have had the opportunity to see firsthand the day-to-day activities of an 
FNP. I have performed detailed patient assessments and used critical thinking to form an 
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evidence-based diagnosis and treatment plan. As a bedside FNP, I have worked with a 
diverse patient population with diabetes and dementia. Early detection of cognitive 
impairment by screening will ideally enable patients and their families to receive care at 
an earlier stage in the disease process, potentially facilitating health, financial, and legal 
decision-making discussions while the patient still retains the capacity to make decisions. 
Scholar 
The DNP project has provided me with a platform to demonstrate specialized 
knowledge in a particular field. This follows the American Association of Colleges of 
Nursing (2006) that proposes that the final DNP project should demonstrate the 
integration of the student's work and establish the foundations for future scholarships 
(Moran et al., 2017). The DNP project plays a significant role in doctoral education and 
encourages DNP students to engage in academic practice; it has provided a way for me to 
accomplish my professional ambitions. I intend to make further scholarly contributions to 
improve healthcare services and add to nursing knowledge.  
Project Manager 
As the project manager, while developing the CPG for Early Screening for 
Dementia in DM I was privileged to collaborate with a committed and encouraging group 
of experts who offered valuable input. Their recommendations on the CPG helped me 
establish a more comprehensive and detailed dementia and DM guideline. I found that the 
expert panel was eager to assist and, within the allotted time, completed the AGREE II 
appraisal. I was responsible for providing the expert panel packet, including the 
Literature Review Matrix, Disclosure for Anonymous Questionnaires Form, AGREE II 
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instrument, and the CPG, as the project manager. I summarized the AGREE II data once 
the AGREE II had been completed and returned to me. 
Challenges, Solutions, and Insights Gained 
Locating research on dementia prevention in the DM population at the beginning 
of the project posed several challenges. The most important obstacle of this project was 
finding literature for an early screening CPG in DM. No CPGs existed on the subject. 
Still, I was hopeful that the solution was evidence-based literature. I consulted the 
Walden Librarian, who provided invaluable assistance and supporting literature on 
dementia and DM. I was able to pull comprehensive data together to construct the 
guidelines I developed. This initiative has been one of the most important challenges in 
my educational career. I tried tirelessly to overcome the obstacles to finding practical 
guidelines that could be adapted to meet the practice settings' needs. I spent long hours 
researching the levels of evidence and how they pertain to research. As a result, I have 
grown professionally and academically through this pursuit. 
Project Experience and Long-Term Goals 
The ever-changing healthcare system and my burning desire to acquire knowledge 
inspired me to seek a career as a DNP. The project development process has helped me 
develop my competency and confidence in translating theory and research into EBP. The 
project development experience opened my interest in projects to integrate practice with 
EBP. This experience also helped me to develop competencies to discuss conceptual 
models and theories. Through being mentored, I have also learned that I can mentor 
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others through the evidence-to-practice journey. With my education advancement, I can 
continue to be an agent of social change in the nursing profession.  
Summary 
The central concept of this DNP project was to bring awareness to the importance 
of early screening for dementia for patients with DM. Searching through the literature 
was a tedious task, especially since there are no published guideline for practitioners to 
use for early screening for dementia in DM. In carrying out this CPG DNP project, I 
developed evidence-based interventions to provide healthcare consumers and the 
profession with interventions to minimize memory loss and optimize self-care 
management in adult patients with DM. The CPG development for the facility should 
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Appendix B: Disclosure to Expert Panelist Form for Anonymous Questionnaires  
To be given to expert panelist prior to collecting questionnaire responses—note that 
obtaining a “consent signature” is not appropriate for this type of questionnaire and 
providing respondents with anonymity is required.  
  
Disclosure to Expert Panelist:  
You are invited to take part in an expert panelist questionnaire for the doctoral project 
that I am conducting.  
  
Questionnaire Procedures:  
If you agree to take part, I will be asking you to provide your responses anonymously, to 
help reduce bias and any sort of pressure to respond a certain way. Panelists’ 
questionnaire responses will be analyzed as part of my doctoral project, along with any 
archival data, reports, and documents that the organization’s leadership deems fit to 
share. If the revisions from the panelists’ feedback are extensive, I might repeat the 
anonymous questionnaire process with the panel of experts again.  
  
Voluntary Nature of the Project:  
This project is voluntary. If you decide to join the project now, you can still change your 
mind later.  
  
Risks and Benefits of Being in the Project:  
Being in this project would not pose any risks beyond those of typical daily professional 




I might know that you completed a questionnaire, but I will not know who provided 
which responses. Any reports, presentations, or publications related to this study will 
share general patterns from the data, without sharing the identities of individual 
respondents or partner organization(s). The questionnaire data will be kept for a period of 
at least 5 years, as required by my university.  
  
Contacts and Questions:  
If you want to talk privately about your rights in relation to this project, you can call my 
university’s Advocate via the phone number 612-312-1210. Walden University’s ethics 
approval number for this study is 09-08-20-0501311.  
  





Appendix C: AGREE II Tool for Evaluation of Clinical Practice Guideline 
Rating Scale: (1) Strongly Disagree (2) Disagree (3) Partially Disagree (4) Neutral (5) 
Partially Agree (6) Agree (7) Strongly Agree 
 
Domain 1: Scope and Purpose 
 
1. The overall objective of the guideline is specifically described.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
2. The health question covered by the guideline is specifically described.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
3. The population to whom the guideline is meant to apply is specifically described. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Domain 2: Stakeholder Involvement 
 
4. The guideline evaluators include individuals that are considered experts.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
5. The views and preferences of the target population have been sought. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
6. The target users are clearly defined. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Domain 3: Rigour and Development 
 
7. Systematic methods were used to search for evidence. 
 
1 2 3 4 5 6 7  
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  Strongly Disagree      Strongly Agree 
 
8. The criteria for selecting the evidence are clearly described. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
9. The strengths and limitations of the body of evidence are clearly described. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
10. The methods for formulating the recommendations are clearly described. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
11. The health benefits, side effects, and risks have been considered in formulating the 
recommendations. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
12. There is an explicit link between the recommendations and the supporting evidence. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
13. The guideline has been externally reviewed by experts prior to its publication. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
14. A procedure for updating the guideline is provided. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Domain 4: Clarity of Presentation 
 
15. The recommendations are specific and unambiguous. 
 
1 2 3 4 5 6 7  




16. The different options for management of the condition or health issue are clearly 
presented.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
17. Key recommendations are easily identifiable. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Domain 5: Applicability 
 
18. The guideline describes facilitators or barriers to its application. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
19. The guideline provides advice and/or tools on how the recommendations can be put 
into practice. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
20. The potential resource implications of applying the recommendations have been 
considered.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
21. The guideline presents monitoring and/or auditing criteria. 
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Domain 6: Editorial Independence 
 
22. The views of the funding body have not influenced the content of the guideline. 
 
1 2 3 4 5 6 7  




23. Competing interests of guideline development group members have been recorded 
and addressed.  
 
1 2 3 4 5 6 7  
  Strongly Disagree      Strongly Agree 
 
Overall Assessment of Guideline 
 
1. Rate the overall quality of this guideline. 
 
1 2 3 4 5 6 7 
 
Lowest     Highest  
possible      possible 
quality     quality 
 
 














Appendix D:Clinical Practice Guideline 
Procedure  
• The early screening for dementia assessment will be performed at the primary 
care setting upon each admission and annually.  
• If the patient answers yes to any of the risk assessment questions to the early 
screening assessment the provider will be informed, the provider will decide on 
the best next step which may include 
o a cognitive assessment using a brief structured tool such as the Mini-Cog 
(Cordel et al., 2013),  
o laboratory tests, CT, and/or MRI imaging or  
o be referred to a memory clinic for a multidisciplinary evaluation and 
treatment between neurologists and diabetologists for early dementia.  
 (Cordel et al., 2013). 
Question 
• What early screening can be performed by the facility to identify early 
cognitive impairment in diabetes mellitus populations? 
 
Population 
The early screening for cognitive impairment in diabetes mellitus protocol will be 
performed on  all patients who have diabetes at the primary care clinic.  
 
Recommendations 
There is a lack of knowledge and available resources for early screening for 
cognitive impairment in diabetes mellitus populations.  
 
• Dementia and DM are common long-term disorders that can coexist for many 
older people. In the absence of a cure, people with dementia require prompt 
diagnosis and evidence-based treatment to delay disease progression leading to 
adverse outcomes (Biessels & Whitmer, 2019) and enhance health-related 
quality of life (Michalowsky et al., 2019). 
• Cognitive impairment screening is usually not recommended for the general 
population based on no current treatment that changes the impairment. The 
recommendations for people with diabetes suggest that early diagnosis can 
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help reduce risks associated with diabetes care and improve the management of 
diabetes (Biessels & Whitmer 2019). 
• Because cognitive impairment often remains unrecognized, routine screening 
for cognitive impairment in elderly patients with DM is increasingly advocated 
(Janseen et al., 2019). 
• The U.S. Preventive Services Task Force recognized that the use of cognitive 
impairment assessment tools can increase the detection of cognitive 




• DM is one of the world's leading chronic illnesses that cause impairment and 
mortality and is a major contributing factor to dementia (Kim et al., 2019). 
• Diabetes is a recognized risk factor for cognitive impairment, with evidence 
showing that it affects performance in numerous cognitive domains and puts 
persons at increased risk of dementia (Rawlings et al., 2017).  
• Detection of cognitive impairment can be improved by communicating directly 
about memory changes, language, and the ability to perform routine tasks. The 
healthcare staff can recognize significant cognitive and physical changes in 
patients witnessed over time. Informants, family members, and caregivers may 
provide useful knowledge about cognitive changes (Cordell et al., 2013). 
 
Guideline Monitoring 
• The Guideline should be revised every three years or when new guidelines are 
developed. 
• Barriers to the application of this Guideline should be discussed by the 







Screening for Cognitive Impairment 
YES    NO 
During the past 12 months, have you experienced confusion or 
memory loss that is happening more often or is getting worse? 
During the past 7 days, did you need help with eating?  
During the past 7 days, did you need help with getting dressed? 
During the past 7 days, did you need help with bathing? 
During the past 7 days, did you need help with walking? 
During the past 7 days, did you need help using the toilet? 
During the past 7 days, did you need help to do laundry? 
During the past 7 days did you need help to do housekeeping? 
During the past 7 days, did you need help to do banking? 
During the past 7 days, did you need help to go shopping? 
During the past 7 days, did you need help using the telephone? 
During the past 7 days, did you need help to prepare a meal? 
During the past 7 days, did you need help with transportation? 
During the past 7 days, did you need help from others to 
prepare and take your medications? 
 
Cordell, C. B., Borson, S., Boustani, M., Chodosh, J., Reuben, D., Verghese, J., Thies,  
W., & Fried, L.B.(2013), Alzheimer's Association recommendations for 
operationalizing the detection of cognitive impairment during the Medicare 
annual wellness visit. in a primary care setting. Alzheimer's & Dementia, 9(2), 
141-150. doi:10.1016/j.jalz.2012.09.011 
 
See following page for next actions 
If the patient answers YES TO ANY of the above questions 
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Full dementia evaluation 
• Notify provider who will determine further treatment: 
o Standard laboratory tests include TSH, CBC serum B12, folate, CMP. 
Structural brain imaging including CTMRI (Cordell et al., 2013). 
o Refer the patient to a  memory clinic for a multidisciplinary evaluation and 
treatment between neurologists and diabetologists for early dementia.  
  
If the patient answers NO TO ALL of the above questions, follow-up 
cognitive impairment screening during subsequent annual wellness visits (Cordell 
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